Literature DB >> 28785936

Trends in the Mortality of Hepatocellular Carcinoma in the United States.

Eliza W Beal1, Dmitry Tumin2, Ali Kabir1, Dimitrios Moris1, Xu-Feng Zhang1,3, Jeffery Chakedis1, Kenneth Washburn3, Sylvester Black3, Carl M Schmidt1, Timothy M Pawlik4,5.   

Abstract

INTRODUCTION: Primary liver cancer mortality rates have been increasing in the US, but reported decreases among 35-49 year olds may foreshadow future declines. We sought to use age-period-cohort (APC) modeling to evaluate the contribution of cohort effects to hepatocellular carcinoma (HCC) mortality trends in the US.
METHODS: Data on HCC mortality were obtained from the Centers for Disease Control and Prevention National Center for Health Statistics WONDER Online Multiple Cause of Death database, 1999-2015. Crude mortality rates were plotted by gender and age at death. Gender-specific restricted cubic spline APC models were fit to determine influence of birth cohort on incidence of HCC mortality, in reference to the 1940 birth cohort.
RESULTS: Highest mortality rates were found among men ages 70+, with steepest increase in mortality observed among men 55-69 years old. Similar trends were found among females. Accounting for the cohort effect in the APC model markedly improved model fit (likelihood ratio test p < 0.001). Relative to the 1940 birth cohort, risk of mortality due to HCC was significantly higher in later as well as earlier cohorts.
CONCLUSIONS: HCC-associated mortality continues to increase, secondary to an increase in the risk of HCC-associated mortality in more recent birth cohorts among both men and women.

Entities:  

Keywords:  Hepatocellular carcinoma; Mortality

Mesh:

Year:  2017        PMID: 28785936     DOI: 10.1007/s11605-017-3526-7

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  23 in total

1.  Flexible regression models with cubic splines.

Authors:  S Durrleman; R Simon
Journal:  Stat Med       Date:  1989-05       Impact factor: 2.373

2.  Age-period-cohort models for the Lexis diagram.

Authors:  B Carstensen
Journal:  Stat Med       Date:  2007-07-10       Impact factor: 2.373

3.  Validation and limitation of age-period-cohort model in simulating mortality due to hepatocellular carcinoma from 1940 to 2010 in Japan.

Authors:  Tomoyuki Akita; Masayuki Ohisa; Yuki Kimura; Mayumi Fujimoto; Yuzo Miyakawa; Junko Tanaka
Journal:  Hepatol Res       Date:  2013-07-11       Impact factor: 4.288

Review 4.  Survival following redo hepatectomy vs radiofrequency ablation for recurrent hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Paschalis Gavriilidis; Alan Askari; Daniel Azoulay
Journal:  HPB (Oxford)       Date:  2016-10-27       Impact factor: 3.647

5.  Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma.

Authors:  Ju Dong Yang; W Ray Kim; Ritika Coelho; Teresa A Mettler; Joanne T Benson; Schuyler O Sanderson; Terry M Therneau; Bohyun Kim; Lewis R Roberts
Journal:  Clin Gastroenterol Hepatol       Date:  2010-09-08       Impact factor: 11.382

Review 6.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors.

Authors:  Giovanna Fattovich; Tommaso Stroffolini; Irene Zagni; Francesco Donato
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

7.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.

Authors:  Robert J Wong; Maria Aguilar; Ramsey Cheung; Ryan B Perumpail; Stephen A Harrison; Zobair M Younossi; Aijaz Ahmed
Journal:  Gastroenterology       Date:  2014-11-25       Impact factor: 22.682

8.  Age-Period-Cohort Analysis of Liver Cancer Mortality in Korea.

Authors:  Jihwan Park; Yon Ho Jee
Journal:  Asian Pac J Cancer Prev       Date:  2015

9.  Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States.

Authors:  Sean F Altekruse; S Jane Henley; James E Cucinelli; Katherine A McGlynn
Journal:  Am J Gastroenterol       Date:  2014-02-11       Impact factor: 10.864

Review 10.  Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.

Authors:  Tarik Asselah; Nathalie Boyer; David Saadoun; Michele Martinot-Peignoux; Patrick Marcellin
Journal:  Liver Int       Date:  2016-01       Impact factor: 8.754

View more
  18 in total

1.  Combination of sorafenib and Valproic acid synergistically induces cell apoptosis and inhibits hepatocellular carcinoma growth via down-regulating Notch3 and pAkt.

Authors:  Wanhu Zhu; Qing Liang; Xu Yang; Yan Yu; Xiaoying Shen; Guangchun Sun
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

2.  Evaluation of the ACS NSQIP Surgical Risk Calculator in Elderly Patients Undergoing Hepatectomy for Hepatocellular Carcinoma.

Authors:  Kota Sahara; Anghela Z Paredes; Katiuscha Merath; Diamantis I Tsilimigras; Fabio Bagante; Francesca Ratti; Hugo P Marques; Olivier Soubrane; Eliza W Beal; Vincent Lam; George A Poultsides; Irinel Popescu; Sorin Alexandrescu; Guillaume Martel; Workneh Aklile; Alfredo Guglielmi; Tom Hugh; Luca Aldrighetti; Itaru Endo; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2019-04-01       Impact factor: 3.452

3.  Comparison of Models for Predicting Quality of Life After Surgical Resection of Hepatocellular Carcinoma: a Prospective Study.

Authors:  Chong-Chi Chiu; King-Teh Lee; Hao-Hsien Lee; Jhi-Joung Wang; Ding-Ping Sun; Chien-Cheng Huang; Hon-Yi Shi
Journal:  J Gastrointest Surg       Date:  2018-06-18       Impact factor: 3.452

4.  Reduced Rates of Post-Transplant Recurrent Hepatocellular Carcinoma in Non-Alcoholic Steatohepatitis: A Propensity Score Matched Analysis.

Authors:  Ryan Lamm; Peter J Altshuler; Keyur Patel; Osama Shaheen; Angel Paulo Amante; Jesse Civan; Warren Maley; Adam Frank; Carlo Ramirez; Jaime Glorioso; Ashesh Shah; Hien Dang; Adam S Bodzin
Journal:  Transpl Int       Date:  2022-07-05       Impact factor: 3.842

5.  Is there an optimal staging system or liver reserve model that can predict outcome in hepatocellular carcinoma?

Authors:  Veeravich Jaruvongvanich; Tomoki Sempokuya; Linda Wong
Journal:  J Gastrointest Oncol       Date:  2018-08

6.  The Epidemiology, Staging and Outcomes of Sarcomatoid Hepatocellular Carcinoma: A SEER Population Analysis.

Authors:  Dimitrios Giannis; Sara Morsy; Georgios Geropoulos; Stepan M Esagian; Georgios S Sioutas; Dimitrios Moris
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.406

7.  Long-term trends of liver cancer mortality by gender in urban and rural areas in China: an age-period-cohort analysis.

Authors:  Yuanyuan Sun; Yanhong Wang; Mengmeng Li; Kailiang Cheng; Xinyu Zhao; Yuan Zheng; Yan Liu; Shaoyuan Lei; Li Wang
Journal:  BMJ Open       Date:  2018-02-08       Impact factor: 2.692

8.  A simple scoring system to estimate perioperative mortality following liver resection for primary liver malignancy-the Hepatectomy Risk Score (HeRS).

Authors:  Dimitrios Moris; Brian I Shaw; Cecilia Ong; Ashton Connor; Mariya L Samoylova; Samuel J Kesseli; Nader Abraham; Jared Gloria; Robin Schmitz; Zachary W Fitch; Bryan M Clary; Andrew S Barbas
Journal:  Hepatobiliary Surg Nutr       Date:  2021-06       Impact factor: 7.293

9.  Changes in the place of death for older adults with cancer: Reason to celebrate or a risk for unintended disparities?

Authors:  Ramy Sedhom; Pei-Lun Kuo; Arjun Gupta; Thomas J Smith; Fumiko Chino; Michael A Carducci; Karen Bandeen-Roche
Journal:  J Geriatr Oncol       Date:  2020-10-26       Impact factor: 3.599

10.  A quantitative proteomic response of hepatocellular carcinoma Hep3B cells to danusertib, a pan-Aurora kinase inhibitor.

Authors:  Qiaohua Zhu; Xinfa Yu; Zhi-Wei Zhou; Meihua Luo; Chengyu Zhou; Zhi-Xu He; Yong Chen; Shu-Feng Zhou
Journal:  J Cancer       Date:  2018-05-24       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.